Li Xiao-Lin, Zhang Ci-Xian
Department of Cardiology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China.
Department of Cardiology, Xuzhou Clinical School of Xuzhou Medical College, Xuzhou, Jiangsu 221009, P.R. China.
Oncol Lett. 2016 Nov;12(5):3051-3054. doi: 10.3892/ol.2016.5108. Epub 2016 Sep 9.
Chronic lymphocytic leukemia (CLL) is considered incurable despite advances in management strategies. New drugs targeting cell pathways are currently being developed for the efficient management of CLL. Various strategies involving different targets have been developed, or are currently in the developing stage. A search was conducted in the electronic database PubMed, for pre-clinical as well as clinically controlled trials reporting various strategies against CLL currently under investigation. Novel strategies included use of antibodies, small cell inhibitors, such as spleen tyrosine kinase, LYN, cyclin-dependent kinase, and histone deacetylase inhibitors. The present review examined these new and emerging strategies for the efficient management of CLL. The review involves a discussion of novel strategies being examined worldwide against CLL, including anti-CD20, anti-CD37, anti-CD23, anti-CD40, SYK/LYN inhibitors, BTK inhibitors, p13k inhibitors and recent developments such as the use of cyclin-dependent kinase inhibitors/histone deacetylase inhibitors.
尽管管理策略有所进步，但慢性淋巴细胞白血病（CLL）仍被认为无法治愈。目前正在研发针对细胞通路的新药，以有效管理CLL。已经开发了涉及不同靶点的各种策略，或者这些策略目前正处于研发阶段。在电子数据库PubMed中进行了检索，以查找报告目前正在研究的针对CLL的各种策略的临床前以及临床对照试验。新策略包括使用抗体、小细胞抑制剂，如脾酪氨酸激酶、LYN、细胞周期蛋白依赖性激酶和组蛋白脱乙酰酶抑制剂。本综述研究了这些用于有效管理CLL的新出现的策略。该综述讨论了全球范围内正在研究的针对CLL的新策略，包括抗CD20、抗CD37、抗CD23、抗CD40、SYK/LYN抑制剂、BTK抑制剂、p13k抑制剂以及细胞周期蛋白依赖性激酶抑制剂/组蛋白脱乙酰酶抑制剂的使用等最新进展。
